Menu
Not yet recruiting NCT07067593

Amnioreduction in Polyhydramnios

Observational Polyhydramnios

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Polyhydramnios. Basic parameters: No limits · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Benefits and Risks of Amnioreduction for Management of Pregnant Women With Polyhydramnios

Overview

The aim of this work is to review the indications, procedural complications and outcomes of amnioreduction in pregnancies complicated by polyhydramnios.

Detailed description

Polyhydramnios is the presence of excessive amniotic fluid in the amniotic sac and it's prevalence reaches 2% of all pregnancies . Polyhydramnios is diagnosed based on ultrasound criteria, as an amniotic fluid index (AFI) \>25 cm or maximal vertical pocket \> 8 cm . There is a recognized association of polyhydramnios and adverse pregnancy outcomes, including perinatal death, fetal abnormality and preterm birth . Management of the pregnancy can be problematic, particularly in severe cases, due to issues surrounding maternal discomfort and the risk of preterm birth. Amnioreduction, widely used in the management of polyhydramnios, is an option available to palliate maternal symptomatology and potentially prolong the pregnancy . Previous publications have shown a reduction in the risk for premature rupture of membranes and preterm labor decrease, placental perfusion improvement, and relief of maternal discomfort following amnioreduction

Primary outcome measures

  • Gestational age at delivery [Time frame: 4 months]
  • Rate of PROM [Time frame: 4 months]

Eligibility criteria

Inclusion criteria

  • Pregnant women 20- 38 weeks
  • Patients with polyhydramnios

Exclusion criteria

  • Lethal fetal anomalies
  • Pre labor rupture of membranes
  • Placental separation
  • Chorioamnionitis

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Egypt · 1 center
  • Women's Health Hospital — Asyut

Identifiers

NCT: NCT07067593 · AMN

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗